Avelumab in addition to best supportive care for locally advanced or metastatic urothelial cancer


featured image
Indications: Bladder cancer
Therapeutic Areas: Urological Cancer
Year: 2019

Avelumab in addition to best supportive care (BSC) is in clinical development for the maintenance treatments of adults with locally advanced or metastatic urothelial cancer that did not progress on or following completion of first-line chemotherapy. Urothelial cancer occurs on the lining of the bladder and other parts of the urinary system. In advanced urothelial cancer, cancer has grown into deeper layers including connective tissue or muscle. Metastatic urothelial cancer is when the cancer has spread to other parts of the body, such as the liver or bones. Urothelial cancer usually occurs in patients aged 60 years and older, where patients may have other medical conditions or are not fit enough to be given certain treatments.
Avelumab administered by intravenous infusion is designed to stimulate the body’s own immune system to fight cancer cells. If licensed, avelumab in addition to BSC will offer a maintenance treatment option for patients with locally advanced or metastatic urothelial cancer that did not progress during or following completion of first-line chemotherapy.